Community Health Plan Washington peripheral nerve policy Coverage

Coverage Criteria for Peripheral Nerve Blocks and Ablation

inv-01: Diagnostic and/or Therapeutic Indications

Covered when ANY of the following diagnostic or therapeutic purposes are documented:

Diagnostic or therapeutic indications: A peripheral nerve block is considered medically reasonable and necessary when used for: (A) pain suggestive of classic mononeuritis where neuro-diagnostic studies fail to provide a structural explanation (diagnostic clarification only), (B) peripheral nerve injuries/entrapment or extremity trauma leading to complex regional pain syndrome, (C) when selective peripheral nerve blockade is used diagnostically in unclear clinical pictures, (D) occipital nerve block to confirm occipital neuralgia, (E) suprascapular nerve block to confirm suspected entrapment, (F) trigeminal nerve block (centrally at the trigeminal ganglion, along one of the three divisions, or at peripheral terminal branches), and (G) nerve block or continuous peripheral nerve block as preemptive analgesia when a single injection provides post-surgical pain control during transition to oral analgesics, for procedures causing severe pain not controlled by oral analgesics, when IV/parenteral narcotics would otherwise be required, or when the patient cannot tolerate narcotics due to allergy/side effects.

Referenced CMS LCDs and RCT data.

inv-02: Not Medically Necessary - Frequency/Technique Limits

Considered not medically necessary when ANY of the following frequency/technique limits are met:

Frequency and technique limits: More than three injections per anatomic site (e.g., specific nerve, plexus or branch as defined by CPT code description) in a six-month period; more than two anatomic sites injected at any one session; dry needling of ganglion cysts, ligaments, neuromas, peripheral nerves, tendon sheaths, or their origins/insertions.3 injections/6 months; 2 sites/session

These are explicit coverage limits and may lead to claim denial if exceeded.

inv-03: Insufficient Evidence / Not Supported

Insufficient evidence to support use for the following indications:

Insufficient evidence indications: Treatment of diabetic peripheral neuropathy or peripheral neuropathies caused by other underlying systemic diseases or degenerative/idiopathic causes; genicular nerve blocks for knee osteoarthritis; peripheral nerve blocks with or without electrostimulation, and electrostimulation alone for neuropathies caused by underlying systemic disease.

Genicular nerve blocks specifically noted as very low‑quality and inconsistent evidence.

inv-04: Not Medically Necessary - Peripheral Nerve Ablation

Peripheral nerve destruction using cryoablation, laser, chemical, electrical, or radiofrequency ablation is considered not medically necessary for any of the following:

Ablation exclusions: Sacroiliac joint pain; knee pain; hip pain; shoulder pain; foot or heel pain; headache; intercostal neuralgia; lower extremity pain due to complex regional pain syndrome; lower extremity pain due to peripheral nerve entrapment/compression (e.g., tarsal tunnel syndrome, sciatica); lower extremity pain due to peripheral neuropathy.

Destruction/ablation procedures for these anatomic sites/conditions are considered not medically necessary.

inv-05: Insufficient evidence for other indications

Use not supported when ALL of the following apply:

Unsupported indications: Peripheral or ganglion nerve blocks or neurolysis are being performed for a condition not indicated elsewhere in this policy (including chronic pain) and there is insufficient evidence in the published peer‑reviewed literature to establish efficacy.

Ongoing research exists but effectiveness has not been established for indications not listed in this policy.

Peripheral/ganglion nerve blocks or neurolysis are not supported for indications that are not specifically listed elsewhere in this policy. The published peer-reviewed literature is insufficient to establish efficacy for these uses, including chronic pain, and ongoing research has not demonstrated clear benefit. Providers should therefore consider such procedures investigational or unsupported when the indication is not described in the policy's covered diagnostic or therapeutic sections.

“Dry needling” of ganglion cysts, ligaments, neuromas, peripheral nerves, tendon sheaths and their origins/insertions, or any tissue is explicitly non-covered under this policy. Claims for these procedures are considered non-covered and are not medically necessary.

Destruction of peripheral nerves by cryoablation, laser, chemical, electrical, or radiofrequency methods is considered not medically necessary for the anatomic pain sites and conditions listed in this policy. Specifically, these ablation or neurolytic procedures are not supported for: sacroiliac joint pain, knee pain, hip pain, shoulder pain, foot or heel pain, headache, intercostal neuralgia, and lower extremity pain due to complex regional pain syndrome, peripheral nerve entrapment/compression (e.g., tarsal tunnel, sciatica), or peripheral neuropathy.

Coding and Frequency Limits

Referenced CPT codes for peripheral nerve proceduresCPT

20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s).
20561	Needle insertion(s) without injection(s); 3 or more muscles.
64400	Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular).
64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
64415	Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance, when performed.
64416	Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, continuous infusion by catheter (including catheter placement), including imaging guidance, when performed.
64417	Injection(s), anesthetic agent(s) and/or steroid; axillary nerve, including imaging guidance, when performed.
64418	Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve.
64420	Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level.
64421	Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level (list separately in addition to code for primary procedure).

1–10 of 22

1/3

inv-10: Maximum injections per anatomic site

Maximum injections per anatomic siteNo more than 3 injections per anatomic site within a 6-month period

ApplicabilityApplies to a specific nerve, plexus, or branch as defined by the CPT code description

Denial riskClaims exceeding this frequency are considered not medically necessary and may be denied

inv-11: Maximum anatomic sites per session

Maximum anatomic sites per sessionNo more than 2 anatomic sites injected in any one session

Definition of siteAnatomic site refers to a specific nerve, plexus, or branch as defined by CPT descriptions

Provider Actions, Prior Authorization, and Documentation

Denial Risk

Frequency limits denial risk

Claims exceeding specified frequency or anatomic site limits are at risk of denial. Specifically, more than three injections per anatomic site in a six-month period and more than two anatomic sites injected at a single session are considered not medically necessary and may be denied.

>3 injections per anatomic site in a 6-month period
>2 anatomic sites injected in one session

Documentation Required

Conservative/diagnostic expectation

Conservative management and diagnostic evaluation are expected before proceeding to long-term destructive procedures. Selective peripheral nerve blockade is generally used to clarify diagnosis (diagnostic purpose) rather than as a long-term treatment; documentation should demonstrate prior conservative therapy and diagnostic rationale.

Definitions

inv-18: Selective peripheral nerve blockade

DefinitionInjection of local anesthetic, with or without steroid, to isolate the specific nerve source of pain for diagnostic confirmation or temporary therapeutic relief

Primary purposeUsed diagnostically to clarify etiology when clinical picture is unclear or neuro-diagnostic studies are non-diagnostic (e.g., mononeuritis)

Therapeutic roleMay provide extended short-term relief and can be used as preemptive or perioperative analgesia when appropriate

inv-19: Peripheral nerve destruction/ablation

DefinitionDestruction of peripheral nerves using cryoablation, laser, chemical, electrical, or radiofrequency methods

Coverage stanceThese peripheral nerve destruction/ablation procedures are considered not medically necessary for enumerated anatomic pain sites and conditions

Conservative Treatment Expectations

Frequency and Session Limits for Peripheral Nerve Injections

inv-21: Peripheral nerve block injections

Frequency limitPeripheral nerve block injections: no more than 3 injections per anatomic site within 6 months

ScopeLimit applies per specific nerve, plexus or branch as defined by CPT code descriptions

ConsequenceExceeding this limit is considered not medically necessary and may result in claim denial

inv-22: Peripheral nerve block injections

Session limitPeripheral nerve block injections: no more than 2 anatomic sites injected in one session

DefinitionAnatomic sites are defined by the CPT code descriptions for the specific nerve, plexus or branch

Imaging and Guidance Requirements

Billing Rule

Follow and document imaging guidance per CPT descriptions

When performed, many peripheral nerve injection and neurolytic CPT codes include imaging guidance in their descriptions; use and document imaging guidance per the CPT description.

CPT descriptions note 'including imaging guidance, when performed' for brachial plexus, axillary, sciatic, femoral, and genicular procedures (e.g., 64415, 64417, 64445, 64447, 64454).
Document whether imaging guidance was used to support coding and claims.

Background

Selective peripheral nerve blockade can be used as a diagnostic maneuver to localize nerve-related pain or as a short-term therapeutic measure for peripheral nerve–related pain (examples include post-herniorrhaphy pain, ilioinguinal/iliohypogastric neuralgia, cluneal nerve pain, carpal tunnel, Morton's neuroma, trigeminal or occipital neuralgia). Benefits include the ability to avoid general anesthesia and provide opioid-sparing analgesia; risks include nerve injury, hematoma, infection, systemic toxicity and myotoxicity. When used diagnostically, documentation should describe the diagnostic rationale and the observed response to the block.

Services Not Covered

Not covered: dry needling of ganglion cysts, ligaments, neuromas, peripheral nerves, tendon sheaths and their origins/insertions. In addition, peripheral nerve destruction/ablation by cryoablation, laser, chemical, electrical, or radiofrequency is considered not medically necessary for the anatomic sites and conditions enumerated in this policy (see exclusions for sacroiliac joint, knee, hip, shoulder, foot/heel, headache, intercostal neuralgia, and lower extremity pain related to complex regional pain syndrome, nerve entrapment/compression, or peripheral neuropathy).

OpenPayer

Peripheral Nerve Blocks and Ablation of Peripheral Nerves for Pain Management